150 related articles for article (PubMed ID: 29932084)
21. Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study.
Falcon-Neyra L; Palladino C; Navarro Gómez ML; Soler-Palacín P; González-Tomé MI; De Ory SJ; Frick MA; Fortuny C; Noguera-Julian A; Moreno EB; Santos JL; Olbrich P; López-Cortés LF; Briz V; Neth O;
Medicine (Baltimore); 2016 Jun; 95(24):e3842. PubMed ID: 27310962
[TBL] [Abstract][Full Text] [Related]
22. Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.
Arrabal-Durán P; Rodríguez-González CG; Chamorro-de-Vega E; Gijón-Vidaurreta P; Herranz-Alonso A; Sanjurjo-Sáez M
Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28722790
[TBL] [Abstract][Full Text] [Related]
23. Reassuring Birth Outcomes With Tenofovir/Emtricitabine/Efavirenz Used for Prevention of Mother-to-Child Transmission of HIV in Botswana.
Zash R; Souda S; Chen JY; Binda K; Dryden-Peterson S; Lockman S; Mmalane M; Makhema J; Essex M; Shapiro R
J Acquir Immune Defic Syndr; 2016 Apr; 71(4):428-36. PubMed ID: 26379069
[TBL] [Abstract][Full Text] [Related]
24. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
Palella FJ; Fisher M; Tebas P; Gazzard B; Ruane P; Van Lunzen J; Shamblaw D; Flamm J; Ebrahimi R; Porter D; White K; Hindman J; Elbert E; De-Oertel S; Fralich T
AIDS; 2014 Jan; 28(3):335-44. PubMed ID: 24670520
[TBL] [Abstract][Full Text] [Related]
25. A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicity.
Rojas J; Blanco JL; Sanchez-Palomino S; Marcos MA; Guardo AC; Gonzalez-Cordon A; Lonca M; Tricas A; Rodriguez A; Romero A; Miro JM; Mallolas J; Gatell JM; Plana M; Martinez E
AIDS; 2018 Jul; 32(12):1633-1641. PubMed ID: 29746294
[TBL] [Abstract][Full Text] [Related]
26. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
[TBL] [Abstract][Full Text] [Related]
27. Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS).
Hamzah L; Tiraboschi JM; Iveson H; Toby M; Mant C; Cason J; Burling K; Wandolo E; Jendrulek I; Taylor C; Ibrahim F; Kulasegaram R; Teague A; Post FA; Fox J
Antivir Ther; 2016; 21(4):287-96. PubMed ID: 26460504
[TBL] [Abstract][Full Text] [Related]
28. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people.
Bangsberg DR; Ragland K; Monk A; Deeks SG
AIDS; 2010 Nov; 24(18):2835-40. PubMed ID: 21045636
[TBL] [Abstract][Full Text] [Related]
29. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.
Armenia D; Di Carlo D; Calcagno A; Vendemiati G; Forbici F; Bertoli A; Berno G; Carta S; Continenza F; Fedele V; Bellagamba R; Cicalini S; Ammassari A; Libertone R; Zaccarelli M; Ghisetti V; Andreoni M; Ceccherini-Silberstein F; Bonora S; Di Perri G; Antinori A; Perno CF; Santoro MM
J Antimicrob Chemother; 2017 Mar; 72(3):855-865. PubMed ID: 27999048
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India.
Pujari S; Dravid A; Gupte N; Joshi K; Bele V
Medscape J Med; 2008; 10(8):196. PubMed ID: 18924648
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.
ENCORE1 Study Group
Lancet; 2014 Apr; 383(9927):1474-1482. PubMed ID: 24522178
[TBL] [Abstract][Full Text] [Related]
32. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
Marcelin AG; Charpentier C; Wirden M; Landman R; Valantin MA; Simon A; Katlama C; Yeni P; Descamps D; Aubron-Olivier C; Calvez V
J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
; Carey D; Puls R; Amin J; Losso M; Phanupak P; Foulkes S; Mohapi L; Crabtree-Ramirez B; Jessen H; Kumar S; Winston A; Lee MP; Belloso W; Cooper DA; Emery S
Lancet Infect Dis; 2015 Jul; 15(7):793-802. PubMed ID: 25877963
[TBL] [Abstract][Full Text] [Related]
34. A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa.
Ba S; Raugi DN; Smith RA; Sall F; Faye K; Hawes SE; Sow PS; Seydi M; Gottlieb GS;
Clin Infect Dis; 2018 Oct; 67(10):1588-1594. PubMed ID: 29672676
[TBL] [Abstract][Full Text] [Related]
35. Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort.
Perrier M; Charpentier C; Peytavin G; Lê M; Blondel L; Visseaux B; Joly V; Pinto A; Matheron S; Yazdanpanah Y; Descamps D; Landman R
J Antimicrob Chemother; 2017 Jun; 72(6):1745-1751. PubMed ID: 28186251
[TBL] [Abstract][Full Text] [Related]
36. Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.
Pedrol E; Caro-Murillo AM; Castaño MA; Riera M; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Pulido F; Romero-Palacios A; Aguirrebengoa K; Vera F; Ferrer P; Blanco Ramos JR
HIV Clin Trials; 2015; 16(1):43-8. PubMed ID: 25777189
[TBL] [Abstract][Full Text] [Related]
37. Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.
Nkhoma ET; Rosenblatt L; Myers J; Villasis-Keever A; Coumbis J
PLoS One; 2016; 11(12):e0166982. PubMed ID: 27941989
[TBL] [Abstract][Full Text] [Related]
38. 3D printed, controlled release, tritherapeutic tablet matrix for advanced anti-HIV-1 drug delivery.
Siyawamwaya M; du Toit LC; Kumar P; Choonara YE; Kondiah PPPD; Pillay V
Eur J Pharm Biopharm; 2019 May; 138():99-110. PubMed ID: 29655904
[TBL] [Abstract][Full Text] [Related]
39. Switching from a two-tablet regimen of tenofovir/emtricitabine and efavirenz to a one-tablet regimen may affect patients' perceptions and drug management.
Rotzinger A; Locatelli I; Bugnon O; Fayet Mello A; Parienti JJ; Cavassini M; Schneider MP
HIV Med; 2016 May; 17(5):390-6. PubMed ID: 26688004
[TBL] [Abstract][Full Text] [Related]
40. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
